26 related articles for article (PubMed ID: 1284307)
1. Assessing resource use in oncology patients: a comparison of analyses based on claims data and medical chart review.
Semroc GN; Tierce JC; Fridman M
J Manag Care Pharm; 2003; 9(2 Suppl):6-9. PubMed ID: 14613338
[TBL] [Abstract][Full Text] [Related]
2. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N
Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
[TBL] [Abstract][Full Text] [Related]
3. Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas.
Hansen PB; Johnsen HE; Ralfkiaer E; Jensen L; Gaarsdal E; Hansen NE
Leuk Lymphoma; 1995 Nov; 19(5-6):453-60. PubMed ID: 8590846
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
Silvestri F; Velisig M; Fanin R; Virgolini L; Zaja F; Barillari G; Baccarani M
Leuk Lymphoma; 1995 Feb; 16(5-6):465-70. PubMed ID: 7540461
[TBL] [Abstract][Full Text] [Related]
7. The clinical use of RHG-CSF for malignant lymphomas.
Oyama A; Suzuki H; Ogura M; Ariyoshi Y; Asano S
J Nutr Sci Vitaminol (Tokyo); 1992; Spec No():361-4. PubMed ID: 1284307
[No Abstract] [Full Text] [Related]
8. [New therapy of patients with malignant lymphoma using G-CSF].
Asano S
Nihon Naika Gakkai Zasshi; 1994 Jun; 83(6):924-7. PubMed ID: 7525813
[No Abstract] [Full Text] [Related]
9. Dose-dense chemotherapy for aggressive non-Hodgkin lymphoma.
Anderson-Reitz L
Cancer Nurs; 2006; 29(3):198-206. PubMed ID: 16783118
[TBL] [Abstract][Full Text] [Related]
10. [Non-Hodgkin lymphoma].
Ogawa M
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1143-8. PubMed ID: 8751801
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in elderly patients with aggressive histology lymphoma.
Kouroukis CT; Meyer RM
Ann Hematol; 2001; 80 Suppl 3():B86-8. PubMed ID: 11757717
[No Abstract] [Full Text] [Related]
12. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.
Couderc LJ; Stelianides S; Frachon I; Stern M; Epardeau B; Baumelou E; Caubarrere I; Hermine O
Respir Med; 1999 Jan; 93(1):65-8. PubMed ID: 10464852
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
